Background and study aim: Proper assessment of liver fibrosis and cirrhosis by non- invasive procedures are needed before appropriate management. This study aimed at detecting the role of IL-1α and TGF-β1as non-invasive liver fibrosis markers in chronic liver diseases.
Patients and methods: The subjects included in this study were divided into 4 groups. Group1: 15 chronic HCV patients, group 2: 15 HCC patients, group 3: 15 patients with NAFLD, group 4: 15 healthy control subjects.  Serum IL-1α and TGF-β1 measured by ELISA to patients and control groups with calculation of FIB-4 and APRI score.
Results: IL-1α and TGF-β1 were significantly high in all hepatic patients compared to control group. The highest level of serum TGF-β1 was in HCC patients.  There was a positive correlation between serum IL-1α and ALT, AST, ALP and HCV RNA by PCR. There was a negative correlation between IL-1α and TGF-β1. There was a highly significant positive correlation between TGF-β1 and FIB4, APRI score, ALP and AFP.
Conclusion: Chronic liver diseases including HCV, HCC and NAFLD were associated with higher levels of IL-1α and TGF-β1 than healthy subjects.